TABLE 2

Testing in patients prescribed preexposure prophylaxis for HIV prevention

PrEP medications	Emtricitabine/tenofovir disoproxil fumarate	Emtricitabine/tenofovir alafenamide	Cabotegravir
Initial testing

Human immunodeficiency virus (HIV) antigen/antibody	X	X	X
HIV RNA	X	X	X
Creatinine/estimated creatinine clearance	X	X	X
Rapid plasma reagin syphilis screening	X	X	X
Gonorrhea/chlamydia nucleic acid amplification testing^a	X	X	X
Hepatitis A virus specific immunoglobulin G	X	X	X
Hepatitis B surface antigen	X	X	X
Hepatitis B surface antibody	X	X	X
Hepatitis B core antigen	X	X	X
Hepatitis C virus-specific immunoglobulin G	X	X	X
Pregnancy test^b	X		X
One month

HIV antigen/antibody	X	X	X
HIV RNA			X
Every 2 months

HIV antigen/antibody			X
Rapid plasma reagin syphilis screening^c	Not applicable	Not applicable	X
Gonorrhea/chlamydia nucleic acid amplification testing^a,^c,^d			X
Pregnancy test^b			X
Every 3 months

HIV antigen/antibody	X	X
Creatinine^e	X	X
Rapid plasma reagin syphilis screening	X	X	Not applicable
Gonorrhea/chlamydia nucleic acid amplification testing^a,^d	X	X
Pregnancy test^b	X
Annually

Creatinine^e	X	X	X
Hepatitis C virus-specific immunoglobulin G^f	X	X	X
Lipid panel		X

↵^a3-site testing of self-collected urine or vaginal specimen, pharyngeal swab, and rectal swab.
↵^bUrine pregnancy testing if childbearing potential.
↵^cTesting intervals may be extended to every 4 months.
↵^dGonorrhea testing semiannually and chlamydia testing at least yearly for cisgender women.
↵^eRenal function testing may be performed semiannually.
↵^fHepatitis C virus immunoglobulin G may be tested more regularly and as requested.
Based on information from references 2,6,14,22–25.